OakChart

Cogent Biosciences Inc

COGTHealthcare·Biotechnology·USA·Mid·NASD·Nov 11 • 3:59 PM ET

29.40-2.24 (-7.08%)
2026-11-12 02:59 CET
Market cap
5,116.72 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-407.68 USD m
Free cash flow, TTM
-325.78 USD m
EPS diluted, TTM
-2.50
P/E
-
Compare

Price

COGT against its 20, 50 and 200-day averages
2050200missearnings
30.0035.0040.005.0M9.9MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26COGTclose 29.4020-day 31.0250-day 31.63200-day 35.3929.4052w high52w low

32.8% under the 52-week high of 43.73 on 8 Dec 2025. 52-week low 27.74 on 14 Oct 2026. Last 15 sessions, 18.2% high to low

Volume 2.25× normal · the line is the 50-bar volume average

Profile

COGT
52-week range, 10% of the way up
27.7443.73

Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation and other mutations in KIT exon 17. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Waltham, MA.

IndexRUT
Employees258
IPOMar 29, 2018
Beta0.35
ATR, 14d1.78
Rel volume2.25
Short float11.15%
Insider own10.22%
Inst own104.73%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap5.12B
Enterprise Value4.63B
Income-407.68M
Sales0.00M
Book/sh2.59
Cash/sh4.55
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees258
IPOMar 29, 2018

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B11.33
P/C6.47
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio10.99
Current Ratio10.99
Debt/Eq0.47
LT Debt/Eq0.47
Option/ShortYes / Yes

Earnings

EPS (ttm)-2.50
EPS next Y-1.18
EPS next Q-0.61
EPS this Y-7.28%
EPS next Y48.88%
EPS next 5Y-
EPS past 3/5Y-2.22% 30.89%
Sales past 3/5Y- -
EPS Y/Y TTM0.71%
Sales Y/Y TTM-
EPS Q/Q-9.42%
Sales Q/Q-
EarningsNov 05 AMC
EPS/Sales Surpr.0.00% -

Ownership

Insider Own10.22%
Insider Trans-0.26%
Inst Own104.73%
Inst Trans3.67%
ROA-64.81%
ROE-99.59%
ROIC-53.72%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-5.23%
SMA50-7.05%
SMA200-16.93%
Trades-

Technical

Shs Outstand173.98M
Shs Float156.25M
Short Float11.15%
Short Ratio8.68
Short Interest17.42M
52W High43.73 -32.77%
52W Low27.74 6.00%
Volatility8.79% 5.33%
ATR (14)1.78
RSI (14)43.38
Beta0.35
Rel Volume2.25
Avg Volume2.01M
Volume4,513,611

Performance

Perf Week-6.64%
Perf Month4.66%
Perf Quarter-21.20%
Perf Half Y-14.26%
Perf YTD-17.23%
Perf Year-12.03%
Perf 3Y326.09%
Perf 5Y180.80%
Perf 10Y-
Recom1.17
Target Price55.82
Prev Close31.64
Price29.40
Change %-7.08%

Analyst ratings

latest 10 of 19
DateActionAnalystRating changeTargetImplied
Mar 16, 2026ResumedJJefferiesBuy
Nov 10, 2025UpgradeWWedbushNeutral → Outperform$38+29.3%
Nov 10, 2025UpgradeSStifelHold → Buy$40+36.1%
Oct 16, 2025InitiatedSStifelHold$16-45.6%
Sep 03, 2025InitiatedRRaymond JamesStrong Buy$30+2.0%
Mar 07, 2025InitiatedBScotiabankSector Outperform$17-42.2%
Dec 11, 2024DowngradeNNeedhamBuy → Hold
Feb 26, 2024DowngradeRRobert W. BairdOutperform → Neutral$14 → $8-72.8%
Feb 08, 2024InitiatedCCitigroupBuy$11-62.6%
Dec 11, 2023DowngradeWWedbushOutperform → Neutral$5-83.0%

Peers

Mkt cap
TickerCompanyMkt cap
CLDXCelldex Therapeutics Inc2.37B
RLAYRelay Therapeutics Inc4.36B
ERASErasca Inc5.88B
IDYAIdeaya Biosciences Inc3.16B
CELCCelcuity Inc3.16B
SNYSanofi ADR115.43B
TNGXTango Therapeutics Inc4.36B
INCYIncyte Corp24.92B
RVMDRevolution Medicines Inc39.08B
SNDXSyndax Pharmaceuticals Inc863.37M

Insider trading

latest 14 of 15
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Morris ArleneDirectorAug 27 '26Option Exercise5.3945,510245,49745,510Aug 31 05:01 PM
Morris ArleneDirectorAug 27 '26Sale37.1245,5101,689,4930Aug 31 05:01 PM
ARLENE MORRISDirectorAug 27 '26Proposed Sale36.7245,5101,671,127Aug 27 04:17 PM
Fairmount Healthcare Fund II LDirectorMar 31 '26Proposed Sale34.667,000,000242,620,000Mar 31 09:30 PM
Fairmount Funds Management LLCDirectorMar 31 '26Sale34.667,000,000242,620,0005,503,418Mar 31 09:30 PM
Fairmount Funds Management LLCDirectorJan 22 '26Sale36.403,500,000127,400,0005,503,418Jan 22 08:09 PM
Fairmount Healthcare Fund II LDirectorJan 22 '26Proposed Sale36.403,500,000127,400,000Jan 22 08:05 PM
Kearns EvanChief Legal OfficerDec 26 '25Sale38.7065,0002,515,500109,398Dec 30 04:01 PM
Green John L.Chief Financial OfficerDec 26 '25Sale38.6877,0002,978,360131,834Dec 30 04:01 PM
Sachs JessicaChief Medical OfficerDec 26 '25Sale38.7082,6423,198,245133,938Dec 30 04:01 PM
Robinson John EdwardChief Scientific OfficerDec 26 '25Sale38.7490,0003,486,600140,002Dec 30 04:01 PM
JESSICA SACHSOfficerDec 26 '25Proposed Sale38.7082,6423,198,435Dec 29 09:27 AM
JOHN ROBINSONOfficerDec 26 '25Proposed Sale38.7490,0003,486,276Dec 29 09:08 AM
JOHN GREENOfficerDec 26 '25Proposed Sale38.6877,0002,978,322Dec 29 09:06 AM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
VBRVanguard Morningstar Small-Cap Value ETFAUM: 37.76B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IBBiShares Biotechnology ETFAUM: 11.36B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B

News

latest 14 of 200
  • Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial Results (GlobeNewswire) -6.07% +6.98%
  • Cogent Biosciences to Participate in the Guggenheim Healthcare Innovation Conference (GlobeNewswire)
  • Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) (GlobeNewswire)
  • Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results (GlobeNewswire)
  • Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) (GlobeNewswire)
  • Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress (GlobeNewswire)
  • Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress (GlobeNewswire)
  • Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
  • Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST (GlobeNewswire)
  • Cogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference (GlobeNewswire)
  • Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress (GlobeNewswire)
  • Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results (GlobeNewswire)
  • Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
  • Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026 (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.586-0.586-0.5630.000.0011
2026Q22026-08-10-0.538-0.555-0.5640.000.0012
2026Q12026-05-05-0.530-0.533-0.6000.000.0012
2025Q42026-02-17-0.636-0.575-0.6930.000.0012
2025Q32025-11-03-0.530-0.517-0.5880.000.0012
2025Q22025-08-05-0.612-0.587-0.6420.000.0012
2025Q12025-05-06-0.635-0.593-0.6350.000.0010
2024Q42025-02-25-0.599-0.599-0.6540.000.0011
2024Q32024-11-12-0.640-0.566-0.6410.000.0011
2024Q22024-08-06-0.590-0.557-0.5940.000.0011
2024Q12024-05-07-0.620-0.515-0.6160.000.0010
2023Q42024-02-26-0.630-0.563-0.6270.000.0011
2023Q32023-11-02-0.640-0.501-0.6430.000.009
2023Q22023-08-08-0.590-0.544-0.5900.000.009
2023Q12023-05-09-0.540-0.571-0.5460.000.008
2022Q42023-03-14-0.560-0.517-0.5620.000.007

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-4.160-5.410-4.17822.5010.71
2020FY-16.170-3.842-16.1727.877.92
2021FY-1.870-1.792-1.8660.000.00
2022FY-2.390-2.343-2.3880.000.00
2023FY-2.420-2.320-2.4150.000.00
2024FY-2.451-2.419-2.4620.000.00
2025FY-2.256-2.267-2.2430.000.00
2026FY--2.317--5.44
2027FY--1.185--287.93
2028FY-0.720--759.79
2029FY-2.912--1,403
2030FY-4.572--1,877

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0611015.440.0013.80
2026Q4S2026-11-0511015.440.0013.80
2026Q4S2026-11-0411005.980.0013.80
2026Q4S2026-10-2811005.980.0013.80
2026Q4S2026-10-2511015.980.0013.80
2026Q4S2026-10-2411025.980.0013.80
2026Q4S2026-10-0211135.980.0013.80
2026Q4S2026-09-2911145.980.0013.80
2026Q4S2026-09-0811245.980.0013.80
2026Q4S2026-08-1810236.580.0013.80
2026Q4S2026-08-149237.310.0013.80
2026Q4S2026-08-138227.020.0013.80
2026Q4S2026-08-1110226.660.0013.80
2026Q4S2026-08-1010218.900.0030.10

Estimate history

EPS, annual-3.354-4.598-4.178-16.172-1.866-2.388-2.415-2.462-2.55-2.5004
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.641-0.654-0.635-0.642-0.588-0.693-0.6-0.564-0.643
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual8.369.73422.4997.871000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual7.6217.5147.66632.34843.80669.89386.124110.539161.052174.028
Period201720182019202020212022202320242025MRQ
Shares, quarterly110.458110.539113.931114.003139.902161.052170.818171.642174.028
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.007.8722.509.73
Cost of Goods Sold Incl. D&A4.954.624.403.595.880.15---
Gross Profit-4.95-4.62-4.40-3.59-5.88-0.15---
Selling, General and Administrative Excl. Other417.97328.74271.54204.54141.9675.4038.2753.3844.42
Research and Development291.88265.16228.26170.17115.7555.7725.7443.7138.28
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-422.92-333.36-275.94-208.13-147.84-75.55-31.12-32.18-36.01
Interest Expense4.963.060.000.000.000.000.000.000.00
Unusual Expense7.187.180.00-1.70-1.36-0.3452.10--
Net Income Before Taxes-407.68-328.94-255.86-192.41-140.24-72.27-74.81-31.83-34.53
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-407.68-328.94-255.86-192.41-140.24-72.27-74.81-31.83-34.55
Net Income From Continuing Operations-407.68-328.94-255.86-192.41-140.24-72.27-74.81-31.83-34.55
Net Income-407.68-328.94-255.86-192.41-140.24-72.27-179.21-31.83-34.55
EPS (Recurring)-2.33-2.51-2.46-2.43-2.40-1.87-12.88-4.18-4.60
EPS (Basic, Before Extraordinaries)-2.50-2.55-2.46-2.42-2.39-1.87-16.17-4.18-4.60
EPS (Diluted)-2.50-2.55-2.46-2.42-2.39-1.87-16.17-4.18-4.60
EBITDA-417.97-328.74-271.54-204.54-141.96-75.40-30.40-30.89-34.68
Non-Operating Income (Expense)27.3914.6720.0814.026.242.948.420.341.47
Other After Tax Adjustments0.000.000.000.000.000.000.000.00-0.02
Stock Option Compensation Expense66.6946.0839.7430.6218.3711.696.023.242.44
Price To Sales Ratio------15.810.9813.59
Operating Margin-------395.43-143.02-369.89
Net Margin-------2,276.81-141.49-354.92
Shares Outstanding174.03161.05110.5486.1269.8943.8132.357.677.51
Market Capitalization5,116.725,116.72861.60506.41807.97341.92333.1222.08132.26

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A1.251.371.161.181.151.161.141.16
Gross Profit-1.25-1.37-1.16-1.18-1.15-1.16-1.14-1.16
Selling, General and Administrative Excl. Other115.93101.27102.4598.3282.2174.4273.8072.58
Research and Development73.8569.4474.2174.3867.8461.0561.8960.89
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-117.18-102.64-103.61-99.49-83.36-75.58-74.93-73.73
Interest Expense1.241.221.211.291.460.310.000.00
Unusual Expense0.000.000.007.180.000.000.000.00
Net Income Before Taxes-111.43-96.41-97.35-102.49-80.93-73.53-71.99-67.93
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-111.43-96.41-97.35-102.49-80.93-73.53-71.99-67.93
Net Income From Continuing Operations-111.43-96.41-97.35-102.49-80.93-73.53-71.99-67.93
Net Income-111.43-96.41-97.35-102.49-80.93-73.53-71.99-67.93
EPS (Recurring)-0.64-0.56-0.60-0.66-0.59-0.64-0.63-0.65
EPS (Basic, Before Extraordinaries)-0.64-0.56-0.60-0.69-0.59-0.64-0.63-0.65
EPS (Diluted)-0.64-0.56-0.60-0.69-0.59-0.64-0.63-0.65
EBITDA-115.93-101.27-102.45-98.32-82.21-74.42-73.80-72.58
Non-Operating Income (Expense)7.007.457.475.473.882.372.955.81
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense16.8717.1116.9115.8010.609.7210.0110.00
Shares Outstanding174.03171.64170.82161.05139.90114.00113.93110.54
Market Capitalization5,116.726,614.296,250.045,400.962,006.11817.49681.96861.60

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments900.76287.08265.71260.53219.68242.1937.4278.5941.04
Short Term Receivables0.000.000.000.000.000.002.001.670.83
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets9.599.395.064.432.952.721.170.740.51
Total Current Assets910.36296.47270.77264.97222.63244.9140.5981.0042.38
Net Property, Plant & Equipment23.5426.5630.3431.104.484.757.153.254.11
Total Investments and Advances0.420.007.460.001.251.251.251.251.25
Intangible Assets-----0.00--0.00
Other Assets3.304.864.864.753.730.000.430.421.37
Total Assets937.61327.90313.44300.81232.09250.9249.4285.9349.12
Short Term Debt Incl. Current Port. of LT Debt1.551.561.391.422.322.051.620.000.00
Accounts Payable9.5012.0110.655.843.480.733.181.521.35
Other Current Liabilities52.9042.1326.1319.5811.2710.318.4523.439.84
Total Current Liabilities63.9555.7138.1726.8517.0813.0913.2524.9511.19
Long Term Debt237.2515.9017.4718.230.833.154.410.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.030.000.000.000.000.000.000.759.62
Total Liabilities301.2471.6155.6345.0817.9116.2517.6625.6920.81
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value89.39110.6060.0365.8385.40110.880.000.0077.15
Common Equity546.98145.69197.77189.91128.78123.7931.7660.23-48.85
Total Shareholders Equity636.37256.29257.80255.74214.18234.6731.7660.2328.30
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity636.37256.29257.80255.74214.18234.6731.7660.2328.30
Total Liabilities & Stockholders Equity937.61327.90313.44300.81232.09250.9249.4285.9349.12
Book Value Per Share3.401.322.302.722.943.834.148.02-6.41
Tangible Book Value Per Share3.401.322.302.722.943.834.148.02-6.41
Full-Time Employees2582051641387715725653
Price to Book Ratio11.334.222.093.602.922.930.702.202.00
Return on Assets-51.99-79.79-62.65-52.63-29.93-49.82-47.04-51.17-41.00
Return on Equity-73.70-99.54-74.94-59.69-32.20-56.16-69.21-78.04-63.34
Return on Invested Capital-37.65-94.00-69.90-51.19-33.61-31.46-88.00-57.36-90.29
Quick Ratio14.235.327.099.8713.0418.703.063.253.79
Current Ratio14.235.327.099.8713.0418.703.063.253.79

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-407.68-328.94-255.86-192.41-140.24-72.27-74.81-31.83-34.53
Depreciation4.924.584.353.595.880.150.721.291.32
Other Funds (Non Cash)71.9351.9032.1223.7614.9711.3443.553.112.88
Funds from Operations-330.83-272.45-219.39-165.07-119.39-60.78-30.53-27.43-30.34
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital6.788.0111.6011.440.752.02-5.32-14.08-2.15
Cash from Operating Activities-324.05-264.44-207.79-153.62-118.64-58.76-35.85-41.51-32.49
Capital Expenditures-1.74-1.55-0.57-2.80-6.86-1.720.00-0.03-0.55
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.008.420.20-
Purchase or Sale of Investments-305.90-397.9738.85-95.03-117.860.000.0022.99-9.98
Purchase of Investments-685.94-687.17-255.60-348.80-177.850.000.000.00-47.68
Sale Or Maturity of Investments380.04289.20294.45253.7860.000.000.0022.9937.70
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-307.63-399.5338.28-97.82-124.72-1.728.4223.16-10.53
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock604.67712.00214.45163.54163.5638.06232.200.110.61
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock604.67712.00214.45163.54163.5638.06232.200.110.61
Proceedsfrom Stock Options575.22699.10214.25162.57162.3238.04231.680.000.00
Issuance or Reduction of Debt, Net168.15215.130.000.000.000.000.000.000.00
Change in Long Term Debt168.15215.130.000.000.000.000.000.000.00
Issuance of Long Term Debt222.78269.770.000.000.000.000.000.000.00
Reduction of Long Term Debt-54.63-54.630.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow-48.90-48.900.000.000.00-0.090.000.0069.74
Other Financing Activities Uses-48.90-48.900.000.000.00-0.090.000.00-2.06
Cash from Financing Activities723.92878.23214.45163.54163.5637.98232.200.1170.35
Net Change in Cash92.24214.2644.94-87.91-79.80-22.51204.77-18.2527.33
Free Cash Flow-325.78-266.00-208.36-156.42-125.50-60.48-35.85-41.55-33.04
Preferred Dividends (Cash Flow)-------0.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments791.13792.30866.38900.76390.89237.85
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets12.4512.5211.439.596.357.16
Total Current Assets803.58804.82877.80910.36397.24245.01
Net Property, Plant & Equipment26.2327.3722.8523.5423.8624.95
Total Investments and Advances0.420.420.420.420.340.00
Other Assets1.911.941.943.304.494.86
Total Assets832.14834.55903.01937.61425.93274.82
Short Term Debt Incl. Current Port. of LT Debt1.581.491.381.551.711.66
Accounts Payable5.947.4913.749.5016.0316.62
Other Current Liabilities65.6050.3242.8552.9044.5140.14
Total Current Liabilities73.1259.3057.9863.9562.2558.42
Long Term Debt242.64242.77237.27237.2558.8559.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.120.090.060.032.372.36
Total Liabilities315.88302.16295.31301.24123.47119.78
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value64.7564.7564.7589.39107.92107.92
Common Equity451.50467.63542.94546.98194.5547.12
Total Shareholders Equity516.26532.39607.69636.37302.46155.04
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity516.26532.39607.69636.37302.46155.04
Total Liabilities & Stockholders Equity832.14834.55903.01937.61425.93274.82
Book Value Per Share2.592.723.183.401.390.41
Tangible Book Value Per Share2.592.723.183.401.390.41
Full-Time Employees---258--
Price to Book Ratio11.3312.1811.3325.5334.727.38
Return on Assets-64.81-68.00-59.71-51.99-72.69-80.62
Return on Equity-99.59-109.74-85.72-73.70-95.40-107.55
Return on Invested Capital-14.68-12.44-11.52-11.73-22.40-34.35
Quick Ratio10.9913.5715.1414.236.384.19
Current Ratio10.9913.5715.1414.236.384.19

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-111.43-96.41-97.35-102.49-80.93-73.53
Depreciation1.251.371.161.141.151.16
Other Funds (Non Cash)17.2516.4316.1422.1110.749.99
Funds from Operations-92.93-78.61-80.06-79.24-69.05-62.38
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital12.141.34-6.830.134.767.83
Cash from Operating Activities-80.79-77.27-86.88-79.11-64.29-54.54
Capital Expenditures-0.11-0.37-0.45-0.81-0.07-0.13
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments37.4214.65-36.01-321.96-154.989.04
Purchase of Investments-74.07-82.81-133.84-395.22-224.07-67.88
Sale Or Maturity of Investments111.4997.4697.8373.2669.0876.92
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities37.3114.28-36.46-322.77-155.058.91
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.00---0.00-
Change in Capital Stock79.762.9652.54469.42217.600.01
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock79.762.9652.54469.42217.600.01
Proceedsfrom Stock Options71.800.0045.71457.71216.560.58
Issuance or Reduction of Debt, Net0.000.000.00168.15-0.2347.22
Change in Long Term Debt0.000.000.00168.15-0.2347.22
Issuance of Long Term Debt0.000.000.00222.78-0.2347.22
Reduction of Long Term Debt0.000.000.00-54.630.000.00
Net Financing Active Other Cash Flow0.000.000.00-48.900.000.00
Other Financing Activities Uses0.000.000.00-48.900.000.00
Cash from Financing Activities79.762.9652.54588.67217.3747.23
Net Change in Cash36.29-60.04-70.80186.79-1.971.59
Free Cash Flow-80.89-77.64-87.33-79.92-64.35-54.67

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3011.15%17.4M156.3M1.99M
2026-10-1512.62%19.7M155.8M1.94M
2026-09-3012.49%19.5M155.8M1.98M
2026-09-1511.63%18.1M155.8M2.27M
2026-08-3112.05%18.7M155.6M2.39M
2026-08-1411.84%18.4M155.6M2.53M
2026-07-3112.05%17.9M148.5M2.43M
2026-07-1511.15%16.6M148.5M2.42M
2026-06-3011.01%16.4M148.5M2.47M
2026-06-159.06%13.5M148.5M2.16M
2026-05-297.83%11.5M147.1M2.08M
2026-05-157.59%11.2M147.1M2.02M
2026-04-308.14%11.8M144.3M1.99M
2026-04-158.78%12.0M137.1M2.13M
2026-03-3112.87%17.4M135.4M2.09M
2026-03-1311.53%15.6M135.4M2.08M
2026-02-2711.90%16.1M135.4M2.21M
2026-02-1312.03%16.3M135.4M2.46M
2026-01-3013.66%16.9M123.9M3.28M
2026-01-1513.27%16.4M123.9M3.30M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call20.007.6012.009.964.1550.000.000.930-0.0670.006
call21.006.6011.000.003.8340.000.000.887-0.1050.009
call22.005.6010.000.003.5260.000.000.875-0.1010.009
call23.004.709.000.003.2280.000.000.861-0.0970.010
call24.004.506.900.002.1600.000.000.845-0.0920.011
call25.003.606.2011.002.1232.000.000.824-0.0860.012
call26.002.755.100.001.8060.000.000.756-0.1120.014
call27.001.604.800.001.9820.000.000.710-0.1090.016
call28.001.504.8012.902.28518.000.000.628-0.1550.017
call29.000.904.500.002.3780.000.000.575-0.1790.018
call30.000.901.401.150.9078.007.000.478-0.1000.018
call31.000.002.852.151.11875.000.000.440-0.1360.018
call32.000.004.701.751.30319.000.000.380-0.1310.017
call33.000.102.250.451.4694.001.000.349-0.1420.017
call34.000.001.550.151.6212040.000.328-0.1530.017
call35.000.001.100.251.1041,0807.000.178-0.0750.012
call36.000.150.550.201.21619.003.000.166-0.0790.011
call37.000.004.700.501.3205.000.000.156-0.0820.011
call38.000.004.700.301.33125.000.000.139-0.0770.010
call39.000.000.905.801.5151.000.000.141-0.0880.010
call40.000.004.600.201.6051,1025.000.135-0.0910.010
call41.000.004.700.061.69217.000.000.130-0.0930.010
call42.000.000.500.101.4531610.000.143-0.0870.012
call43.000.004.700.791.85551.000.000.121-0.0970.009
call44.000.004.800.001.8360.000.000.109-0.0900.009
call45.000.000.600.201.9494.000.000.106-0.0930.008
call50.000.000.800.232.2811,50910.000.094-0.0990.008
call55.000.004.800.502.56918.000.000.086-0.1050.007
call60.000.002.150.552.62717.000.000.066-0.0870.006
call65.000.004.900.102.68516.000.000.046-0.0670.004
put20.000.004.900.201.8695.000.00-0.070-0.0650.006
put21.000.004.900.001.9120.000.00-0.095-0.0840.008
put22.000.004.900.001.7160.000.00-0.105-0.0810.008
put23.000.004.900.001.5270.000.00-0.117-0.0780.009
put24.000.001.950.701.4551.000.00-0.155-0.0890.011
put25.000.100.600.251.2593612.00-0.176-0.0840.012
put26.000.004.700.001.3550.000.00-0.244-0.1090.014
put27.000.001.000.401.1355621.00-0.290-0.1060.016
put28.000.101.700.701.32013.000.00-0.372-0.1520.017
put29.000.702.101.101.27627.00103-0.425-0.1750.018
put30.000.402.200.501.0332000.00-0.522-0.0970.018
put31.000.954.702.301.96336.000.00-0.560-0.1320.018
put32.001.104.502.001.60439.000.00-0.620-0.1280.017
put33.002.304.903.141.42954.001.00-0.651-0.1380.017
put34.002.605.905.001.58145.000.00-0.672-0.1490.017
put35.004.207.305.101.96621.000.00-0.822-0.0710.012
put36.004.607.903.541.8542.000.00-0.834-0.0750.011
put37.005.5010.004.542.6502.000.00-0.844-0.0780.011
put38.006.5011.004.122.7772.000.00-0.852-0.0810.011
put39.007.5011.900.002.8380.000.00-0.859-0.0840.010
put40.008.5013.000.003.0130.000.00-0.865-0.0860.010
put41.009.5014.000.003.1230.000.00-0.870-0.0880.010
put42.0010.5015.000.003.2280.000.00-0.875-0.0900.009
put43.0011.5016.000.003.3290.000.00-0.879-0.0920.009
put44.0012.5017.000.003.4260.000.00-0.883-0.0940.009
put45.0013.5018.006.603.5200.000.00-0.894-0.0880.008
put50.0018.5023.000.003.9430.000.00-0.906-0.0940.008
put55.0023.5027.900.004.2390.000.00-0.914-0.0990.007
put60.0028.5033.000.004.6230.000.00-0.920-0.1030.007
put65.0033.5038.000.004.9060.000.00-0.954-0.0600.004

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-10-054Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-09-028-KCurrent report2026-09-01SEC
2026-08-314Statement of changes in beneficial ownership of securities2026-08-27SEC
2026-08-27144Filing for proposed sale of securities under Rule 144.SEC
2026-08-13SCHEDULE 13G/ASEC
2026-08-108-KCurrent report2026-08-10SEC
2026-08-10424B5SEC
2026-08-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-108-KCurrent report2026-08-10SEC
2026-07-31SCHEDULE 13GSEC
2026-07-27SCHEDULE 13G/ASEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-118-KCurrent report2026-06-09SEC
2026-05-214Statement of changes in beneficial ownership of securities2026-05-19SEC
2026-05-14SCHEDULE 13G/ASEC
2026-05-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-058-KCurrent report2026-05-05SEC
2026-04-23ARSAnnual report to security holders. 2025-12-31SEC
2026-04-23DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-23DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-09SEC
2026-04-034Statement of changes in beneficial ownership of securities2026-04-01SEC
2026-03-31144Filing for proposed sale of securities under Rule 144.SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-08001.69M1
2026-070000
2026-060000
2026-050000
2026-040000
2026-0300242.62M1
2026-020000
2026-0100127.40M1
2025-120012.18M4
2025-110000

Institutional holders

Manager% owned
FMR LLC15.47%
BlackRock, Inc.10.15%
Jupiter Topco LLC6.17%
VANGUARD PORTFOLIO MANAGEMENT LLC4.72%
VANGUARD CAPITAL MANAGEMENT LLC4.34%
STATE STREET CORP4.08%
Fairmount Funds Management LLC3.22%
DEERFIELD MANAGEMENT COMPANY, L.P.2.93%
TCG Crossover Management, LLC2.84%
PRICE T ROWE ASSOCIATES INC /MD/2.72%

Funds

Fund% owned
CALAMOS STRATEGIC TOTAL RETURN FUND5.29%
Calamos Growth & Income Fund4.06%
Columbia Convertible Securities Fund3.46%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.02%
Miller Market Neutral Income Fund2.93%
iShares Russell 2000 ETF2.50%
VANGUARD SMALL-CAP INDEX FUND2.18%
Lord Abbett Convertible Fund2.15%
State Street(R) SPDR(R) S&P(R) Biotech ETF1.86%
Fidelity Small Cap Growth Fund1.47%

OakChart. COGT. Cached 15 minutes.